ReShape Lifesciences Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for ReShape Lifesciences Inc. (HIND), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are HIND insiders buying or selling?
ReShape Lifesciences Inc. insiders reported no open-market purchases or sales in the last 12 months. Since March 2018, Trabud has recorded 55 Form 4 filings for HIND: 22 buys ($6.9M) and 33 sells ($16.1M).
Source: SEC EDGAR Form 4
Key Statistics (March 2018 – Aug 13, 2024)
Total Form 4 filings
55
SEC EDGAR
Insider filers
16
Insider buys (22)
$6.9M
Insider sells (33)
$16.1M
Insider sentiment
Net sellingNet insider flow of $9.2M in net selling since March 2018.
Recent HIND insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Aug 13, 2024 | Thomas Stankovich | Chief Financial Officer | Sale | 172 | $0.23 | $38.78 | SEC ↗ |
| Nov 8, 2023 | Thomas Stankovich | Chief Financial Officer | Sale | 435 | $0.89 | $386.48 | SEC ↗ |
| Jul 19, 2023 | Thomas Stankovich | Chief Financial Officer | Sale | 106 | $1.47 | $155.82 | SEC ↗ |
| Jul 6, 2023 | Thomas Stankovich | Chief Financial Officer | Purchase | 17.4K | $1.50 | $26.2K | SEC ↗ |
| Mar 7, 2023 | Thomas Stankovich | Chief Financial Officer | Sale | 418 | $8.87 | $3.7K | SEC ↗ |
| Dec 20, 2022 | Thomas Stankovich | Chief Financial Officer | Sale | 372.1K | $0.17 | $62.9K | SEC ↗ |
| Nov 10, 2022 | Thomas Stankovich | Chief Financial Officer | Sale | 8.4K | $0.27 | $2.3K | SEC ↗ |
| Oct 6, 2022 | Thomas Stankovich | CFO | Sale | 8.3K | $0.28 | $2.3K | SEC ↗ |
| Sep 12, 2022 | Thomas Stankovich | Chief Financial Officer | Sale | 4.8K | $0.39 | $1.9K | SEC ↗ |
| Aug 11, 2022 | Thomas Stankovich | Chief Financial Officer | Sale | 4.7K | $0.47 | $2.2K | SEC ↗ |
| Aug 11, 2022 | Barton P. Bandy | President and CEO | Sale | 11.7K | $0.47 | $5.5K | SEC ↗ |
| Jul 6, 2022 | Thomas Stankovich | Chief Financial Officer | Sale | 4.6K | $0.55 | $2.5K | SEC ↗ |
| Jul 6, 2022 | Barton P. Bandy | President and CEO | Sale | 11.4K | $0.55 | $6.3K | SEC ↗ |
| Jun 6, 2022 | Barton P. Bandy | President and CEO | Sale | 11.3K | $0.95 | $10.8K | SEC ↗ |
| Jun 6, 2022 | Thomas Stankovich | Chief Financial Officer | Sale | 4.5K | $0.96 | $4.3K | SEC ↗ |
| Jun 1, 2022 | Thomas Stankovich | Chief Financial Officer | Purchase | 20.0K | $0.92 | $18.4K | SEC ↗ |
| May 12, 2022 | Barton P. Bandy | President and CEO | Sale | 11.4K | $0.77 | $8.8K | SEC ↗ |
| Apr 8, 2022 | Thomas Stankovich | Chief Financial Officer | Sale | 5.0K | $1.13 | $5.7K | SEC ↗ |
| Apr 8, 2022 | Barton P. Bandy | President and CEO | Sale | 11.1K | $1.13 | $12.5K | SEC ↗ |
| Mar 2, 2022 | Thomas Stankovich | CFO | Sale | 3.7K | $1.06 | $3.9K | SEC ↗ |
| Mar 2, 2022 | Barton P. Bandy | President and CEO | Sale | 6.5K | $1.06 | $6.9K | SEC ↗ |
| Feb 2, 2022 | Barton P. Bandy | President and CEO | Sale | 8.3K | $1.22 | $10.2K | SEC ↗ |
| Feb 2, 2022 | Thomas Stankovich | Chief Financial Officer | Sale | 3.7K | $1.22 | $4.5K | SEC ↗ |
| Jan 28, 2022 | Barton P. Bandy | President and CEO | Sale | 7.2K | $1.79 | $12.8K | SEC ↗ |
| Jan 28, 2022 | Thomas Stankovich | Chief Financial Officer | Sale | 3.2K | $1.78 | $5.6K | SEC ↗ |
Showing the 25 most recent of 55 Form 4 filings for ReShape Lifesciences Inc..
Most active HIND insiders
- Thomas Stankovich24 filings
- Barton P. Bandy12 filings
- William J. Plovanic3 filings
- DOMAIN PARTERS VII L P2 filings
- INTERWEST PARTNERS X LP2 filings
Ask anything about HIND insider activity
Use Trabud's AI agent to query ReShape Lifesciences Inc.'s Form 4 history in plain English — "Show me HIND CEO purchases this year" or compare it against any other ticker.
Open the AI agentHIND insider trading FAQ
Are ReShape Lifesciences Inc. insiders buying or selling?
ReShape Lifesciences Inc. insiders reported no open-market purchases or sales in the last 12 months. Since March 2018, Trabud has recorded 55 Form 4 filings for HIND: 22 buys ($6.9M) and 33 sells ($16.1M). Over the full record that is net selling of $9.2M.
How many insiders trade HIND stock?
16 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for ReShape Lifesciences Inc.. The most recent filing was accepted on Aug 13, 2024.
Where does Trabud get HIND insider trading data?
All HIND insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.